Richard Neff
@neffrk.bsky.social
Physician, leading and living in interesting times.
Reposted by Richard Neff
💙 Keep updated with this important information about the Joint Guidelines launch of the Guidelines on CPR 2025, on October 22, 2025, in Rotterdam.
❤️ Access the embedded link of each event here, at no cost.
👉 www.erc.edu/news/save-th...
✅ No pre-registration is required. #EduSky #CPR #ResusSky
❤️ Access the embedded link of each event here, at no cost.
👉 www.erc.edu/news/save-th...
✅ No pre-registration is required. #EduSky #CPR #ResusSky
October 20, 2025 at 3:11 PM
💙 Keep updated with this important information about the Joint Guidelines launch of the Guidelines on CPR 2025, on October 22, 2025, in Rotterdam.
❤️ Access the embedded link of each event here, at no cost.
👉 www.erc.edu/news/save-th...
✅ No pre-registration is required. #EduSky #CPR #ResusSky
❤️ Access the embedded link of each event here, at no cost.
👉 www.erc.edu/news/save-th...
✅ No pre-registration is required. #EduSky #CPR #ResusSky
Reposted by Richard Neff
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial - The Lancet www.thelancet.com/journals/lan...
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
An intensive treatment strategy of rapid up-titration of guideline-directed medication
and close follow-up after an acute heart failure admission was readily accepted by
patients because it reduced sy...
www.thelancet.com
April 16, 2025 at 10:58 AM
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial - The Lancet www.thelancet.com/journals/lan...